Genetic testing and screening of individuals at risk of NF2

Clinical Genetics

Volumn 82, Issue 5, 2012, Pages 416-424

  Evans, D G ^a   Raymond, F L ^b   Barwell, J G ^c   Halliday, D ^d  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Meningioma; Mosaicism; NF2; Predictive testing; Vestibular schwannoma

Indexed keywords

ADULT; AGED; ARTICLE; GENETIC RISK; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MOSAICISM; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; CHROMOSOMES, HUMAN, PAIR 22; ENGLAND; GENES, NEUROFIBROMATOSIS 2; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MOSAICISM; MUTATION; NEUROFIBROMATOSIS 2; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84867660653     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01816.x     Document Type: Article

References (14)

1. Evans DGR, Ramsden RT, Shenton A et al. Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including. MLPA J Med Genet 2007: 44 (7): 424-428.
2. Evans DGR, Baser ME, O'Reilly B et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005: 19: 5-12.
3. Evans DGR, Ramsden R, Birch J. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999: 81: 496-499.
4. Evans DGR, Ramsden RT, Shenton A et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet 2007: 71 (4): 354-358.
5. Evans DGR, Ramsden RT, Shenton A et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? J Neurosurg 2008: 108 (1): 92-96.
6. MacCollin M, Chiocca EA, Evans DG et al. Diagnostic criteria for schwannomatosis. Neurology 2005: 64 (11): 1838-1845.
7. Hadfield KD, Newman WG, Bowers NL et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008: 45 (6): 332-339.
8. Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG. SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 2010: 47: 567-568.
9. Evans DGR, Newton V, Neary W et al. Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet 2000: 37: 944-947.
10. King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans DGR. Spinal tumors in neurofibromatosis type 2: is emerging knowledge of genotype predictive of natural history?. J Neurosurg Spine 2005: 2 (5): 574-579.
11. Evans DG, Watson C, King A, Wallace A, Baser ME. Multiple meningiomas: differential involvement of NF2 in children and adults. J Med Genet 2005: 42 (1): 45-48.
12. Evans DG, Wallace A. An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J Med Genet 2009: 46 (11): 792.
13. Evans DGR, Baser ME, O'Reilly B et al. Management of the patient and family with Neurofibromatosis 2: A consensus conference statement. Brit J Neurosurg 2005: 19: 5-12.
14. Kluwe L, Friedrich RE, Tatagiba M, Mautner VF. Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med 2002: 4 (1): 27-30.